IMPURITIES AVAILABLE FOR 'Brigatinib'

Omsynth Lifesciences Pvt. Ltd. is one of the leading manufacturer and exporter of Brigatinib. Brigatinib is a targeted oral tyrosine kinase inhibitor (TKI) used in the treatment of ALK-positive non-small cell lung cancer (NSCLC), particularly in patients who are resistant to or intolerant of prior ALK inhibitors like crizotinib. It inhibits anaplastic lymphoma kinase (ALK) as well as other kinases such as ROS1, EGFR (including some mutant forms), and FLT3, thereby blocking cancer cell proliferation and survival. Brigatinib is known for its ability to penetrate the blood-brain barrier, offering effective control of brain metastases in ALK-positive NSCLC. It is administered orally, typically once daily, with a recommended dose escalation schedule to minimize early pulmonary side effects. Common adverse effects include nausea, fatigue, increased blood creatine phosphokinase (CPK), diarrhea, and cough. Serious but less common effects include interstitial lung disease, hypertension, and bradycardia. Regular monitoring of liver function, blood pressure, and respiratory status is advised during therapy. Buy high quality Brigatinib from Omsynth Lifesciences.